Clinical Trials on Transitional Cell, Carcinoma in Japan

Total 1167 results

GlaxoSmithKline

Active, not recruiting

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM-3)

Multiple Myeloma

United States, Australia, Spain, Bulgaria, Poland, Belgium, France, Germany, Italy, Hungary, United Kingdom, Greece, Russian Federation, Brazil, China, Korea, Republic of, Japan, Canada, Netherlands
Pfizer

Recruiting

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i)

Breast Neoplasms | Prostate Cancer | Adenocarcinoma of Lung | Solid Tumors | Liposarcoma | CRC

China, United States, United Kingdom, Mexico, Czechia, Japan, Slovakia, Argentina
ppharmaand GmbH
Bristol-Myers Squibb; Gynecologic Oncology Group; European Network of Gynaecological... and other collaborators

Active, not recruiting

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response

United States, United Kingdom, Korea, Republic of, Russian Federation, Canada, Denmark, Taiwan, New Zealand, Ireland, Japan, Spain, Australia, Israel, Italy, Greece, Sweden, Czechia, Finland, Poland, Belgium, Germany, Romania, Singa... and more
Daiichi Sankyo
AstraZeneca

Recruiting

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Gastroesophageal Junction Adenocarcinoma | Gastric Cancer, Adenocarcinoma

Hong Kong, Korea, Republic of, France, United Kingdom, Spain, China, Ireland, Brazil, Japan, Singapore, Belgium, Israel, Russian Federation, Argentina, Chile, Hungary, Poland, Portugal, Taiwan, Turkey, Ukraine, Germany, Romania, Italy
Janssen Research & Development, LLC

Active, not recruiting

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Israel, Japan, Canada, Netherlands, Denmark, Sweden, Korea, Republic of, Russian Federation, Greece
Novartis Pharmaceuticals

Active, not recruiting

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i)

Melanoma

Italy, Czechia, Germany, Hungary, Canada, United States, Argentina, Australia, Austria, France, Israel, Russian Federation, Spain, Sweden, United Kingdom, Thailand, Belgium, Brazil, Greece, Switzerland, Mexico, Netherlands, Denmark, C... and more
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy (SunRISe-1)

Urinary Bladder Neoplasms

United States, Belgium, Korea, Republic of, Germany, Italy, France, Spain, Canada, United Kingdom, Greece, Japan, Australia, Netherlands, Portugal, Russian Federation, Ukraine
Amgen

Completed

Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma (ARROW)

Multiple Myeloma

Canada, Denmark, Finland, France, Italy, Spain, Sweden, United Kingdom, Czechia, Poland, United States, Belgium, Hungary, New Zealand, Australia, Germany, Japan, Greece, Norway, Romania
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, United States, Spain, Australia, Japan, France, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, Czechia, Denmark, Germany, Korea, Republic of, United Kingdom, Poland
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, Denmark, United States, Spain, Australia, Japan, France, Korea, Republic of, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, United Kingdom, Czechia, Germany, Poland
Janssen Research & Development, LLC

Active, not recruiting

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Multiple Myeloma

Australia, Poland, United Kingdom, United States, Belgium, Germany, Spain, Argentina, Portugal, Bulgaria, Romania, Serbia, Turkey, Ukraine, Japan, Greece, Korea, Republic of, Brazil, Russian Federation, Hungary, Czechia, Croatia, Ge... and more
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

Melanoma

Spain, Italy, Poland, Brazil, Australia, Chile, Canada, Portugal, Turkey, Germany, Greece, Israel, Sweden, New Zealand, United States, Belgium, France, Taiwan, United Kingdom, South Africa, Denmark, Argentina, Colombia, Japan, Switzerland
Jazz Pharmaceuticals
BeiGene, Ltd.

Recruiting

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01)

Gastroesophageal Adenocarcinoma | Esophageal Adenocarcinoma | Gastric Neoplasms

Korea, Republic of, Belgium, Japan, China, Netherlands, Spain, Germany, United Kingdom, Malaysia, Portugal, France, Italy, Australia, Taiwan, Turkey, Thailand, Argentina, Mexico, Ireland, Estonia, Serbia, Romania, Canada, Poland, Brazil, ... and more
Bristol-Myers Squibb

Terminated

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8)

Urinary Bladder Neoplasms

United States, Netherlands, Italy, Argentina, Australia, Austria, Brazil, Canada, Chile, France, Germany, Greece, Israel, Japan, Russian Federation, Spain, Sweden
Janssen Research & Development, LLC

Active, not recruiting

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3)

Multiple Myeloma

Canada, United States, Belgium, Korea, Republic of, United Kingdom, Sweden, Italy, Denmark, Japan, Taiwan, China, Germany, Spain, France, Netherlands, Turkey, Russian Federation, Poland, Greece, Argentina, Brazil
GlaxoSmithKline

Active, not recruiting

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7)

Multiple Myeloma

Australia, Japan, Spain, Germany, Poland, Belgium, Israel, Italy, Russian Federation, Canada, New Zealand, Korea, Republic of, China, Brazil, Czechia, United States, Netherlands, United Kingdom, Greece, France
AbbVie
Genentech, Inc.

Completed

A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy (Bellini)

Relapsed/Refractory Multiple Myeloma

United States, Australia, Brazil, Canada, France, Germany, Hungary, Ireland, Italy, Japan, Korea, Republic of, Russian Federation, Spain, Taiwan, Ukraine, United Kingdom
Amgen

Completed

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ARROW2)

Relapsed or Refractory Multiple Myeloma

France, Czechia, Sweden, United States, Greece, Spain, Finland, Romania, Germany, Japan, Netherlands, Turkey, Austria, Bulgaria, Lithuania, Russian Federation, Slovakia
Amgen
Zai Lab (China only)

Active, not recruiting

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101)

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China, United States, France, Belgium, Brazil, Korea, Republic of, Canada, Czechia, Spain, Greece, Denmark, Taiwan, Thailand, Norway, Turkey, Latvia, Sweden, Japan, Malaysia, Romania, Australia, Argentina, Peru, Israel, Lithuania, Estonia, ... and more
AstraZeneca

Active, not recruiting

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer (POTOMAC)

Non-muscle-invasive Bladder Cancer

France, Spain, Belgium, Canada, Poland, Germany, Japan, Russian Federation, United Kingdom, Austria, Australia, Netherlands
Bristol-Myers Squibb

Completed

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

Lung Cancer - Non Small Cell Squamous

Belgium, Brazil, China, Germany, Hong Kong, Japan, Korea, Republic of, Taiwan, Thailand, United States, Spain, Australia, Italy, Netherlands, United Kingdom, Denmark, France, Argentina, Austria, Canada, Chile, Colombia, Czechia, Hungary, Irela... and more
Pfizer

Completed

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Metastatic or Unresectable Cutaneous Melanoma

United States, Spain, Canada, Italy, United Kingdom, Germany, Korea, Republic of, France, Australia, Czechia, Russian Federation, Turkey, Israel, Netherlands, Greece, Hungary, Japan, Portugal, Argentina, Austria, Belgium, Brazil, Po... and more
Celgene

Completed

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (OPTIMISMM)

Multiple Myeloma

United States, Spain, United Kingdom, Italy, Israel, Portugal, Germany, Turkey, Greece, Ireland, Austria, Norway, Netherlands, Denmark, Poland, France, Russian Federation, Canada, Finland, Japan, Puerto Rico, Sweden
Janssen Research & Development, LLC

Recruiting

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6)

Relapsed or Refractory Multiple Myeloma

Germany, Korea, Republic of, Italy, France, Japan, Israel, Belgium, Australia, Denmark, Sweden, Brazil, China, Spain, Czechia, Turkey, Poland, Netherlands, Argentina, Canada, United Kingdom, Greece, India
Amgen

Recruiting

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer (FORTITUDE-102)

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, China, United States, Israel, Italy, Spain, Switzerland, Canada, Australia, Germany, United Kingdom, Austria, France, Japan, Taiwan, Belgium, Poland, Thailand, Czechia, Singapore, Hungary, Argentina, Brazil, Romania, Portuga... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Gastric Neoplasms | Gastroesophageal Junction Adenocarcinoma

United States, Australia, Brazil, Chile, China, France, Germany, Guatemala, Ireland, Israel, Italy, Japan, Korea, Republic of, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Amgen

Completed

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. (CANDOR)

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

Canada, Belgium, Spain, United States, Korea, Republic of, Australia, Czechia, Taiwan, Hungary, Austria, Romania, Japan, United Kingdom, Greece, Turkey, Bulgaria, France, Russian Federation, Poland
Celgene

Withdrawn

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ALUMMINATE)

Multiple Myeloma

China, Australia, United States, Argentina, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Korea, Republic of, Norway, Portugal, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom
AbbVie
Roche-Genentech

Active, not recruiting

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Multiple Myeloma

United States, Australia, Canada, China, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Russian Federation, Singapore, Spain, Sweden, Turkey, Ukraine, United Kingdom
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Urinary Bladder Neoplasms

United States, Japan, China, Korea, Republic of, France, Belgium, Czechia, Taiwan, Italy, Poland, United Kingdom, Spain, Germany, Australia, Brazil, Argentina, India
Sanofi
Regeneron Pharmaceuticals

Terminated

Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

Polymyalgia Rheumatica

Argentina, Estonia, France, Japan, United States, Australia, Belgium, Canada, Germany, Hungary, Israel, Italy, Netherlands, Russian Federation, Switzerland, United Kingdom, Spain
Pfizer

Active, not recruiting

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)

Melanoma

Canada, United States, Spain, Germany, Korea, Republic of, Australia, Czechia, Netherlands, France, Hungary, United Kingdom, Switzerland, Singapore, Russian Federation, Italy, Japan, Israel, Brazil, Portugal, Mexico, Greece, Argen... and more
Pfizer

Recruiting

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)

Multiple Myeloma

Japan, Belgium, United States, Netherlands, Australia, Austria, Taiwan, China, Spain, Canada, Israel, Germany, Italy, Czechia, Korea, Republic of, Norway, Finland, France, Sweden, Brazil, Greece, Turkey, United Kingdom, Hungary, Poland, I...
Novartis Pharmaceuticals

Completed

Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma (PANORAMA-1)

Multiple Myeloma

China, United States, Italy, Taiwan, Egypt, Japan, Turkey, Germany, Netherlands, Canada, Australia, Austria, Israel, Sweden, United Kingdom, Korea, Republic of, Spain, Hong Kong, Thailand, France, Belgium, Norway, South Africa, Brazil, ... and more
Millennium Pharmaceuticals, Inc.

Completed

Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

Hematopoietic Stem Cells

United States, Spain, Taiwan, Australia, Canada, Singapore, Korea, Republic of, Mexico, Switzerland, Japan, Germany, Norway, Israel, Russian Federation, Hungary, United Kingdom, Italy, Romania, Brazil, France, Austria, Belgium, Port... and more
Amgen

Completed

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION)

Multiple Myeloma

Korea, Republic of, China, Spain, Taiwan, United States, Netherlands, Australia, Singapore, New Zealand, United Kingdom, Israel, France, Japan, Italy, Czechia, Belgium, Argentina, Austria, Bulgaria, Canada, Germany, Greece, Hungary, M... and more
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

Melanoma

Poland, Australia, Canada, United States, Argentina, Austria, Belgium, Brazil, Chile, China, Colombia, France, Germany, India, Ireland, Israel, Italy, Japan, Korea, Republic of, New Zealand, South Africa, Spain, Sweden, Switzerland, Turkey and more
Merck Sharp & Dohme LLC

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Von Hippel-Lindau Disease | Pancreatic Neuroendocrine Tumor | Pheochromocytoma/Paraganglioma | Advanced Gastrointestinal Stromal Tumor | HIF-2α Mutated Cancers

Canada, United States, Denmark, France, Germany, Hungary, Italy, Russian Federation, Spain, Sweden, Turkey, Israel, United Kingdom, Netherlands, Australia, China, Singapore, Japan
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate548)

Brain Neoplasms

United States, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Israel, Italy, Japan, Netherlands, Norway, Poland, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus)

Malignant Melanoma

Canada, Italy, Czechia, Australia, France, Greece, Israel, Russian Federation, Sweden, United Kingdom, Hungary, Slovakia, Slovenia, Japan, Turkey, Argentina, Finland, Norway, Brazil, Latvia, Lithuania, Poland, Portugal
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)

Brain Cancer

United States, Canada, Belgium, Spain, Australia, Netherlands, United Kingdom, Denmark, Norway, Japan, Sweden, France, Poland, Austria, Germany, Israel, Italy, Russian Federation, Switzerland
Pfizer

Recruiting

MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (MAGNETISMM-5)

Multiple Myeloma

China, Korea, Republic of, Taiwan, United States, France, Sweden, Australia, Japan, Spain, Czechia, United Kingdom, Canada, Germany, New Zealand, Italy, Poland, Netherlands, Austria, Mexico, Finland, Argentina, Belgium, Brazil, Greece, ... and more
Bristol-Myers Squibb

Recruiting

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Canada, Taiwan, United States, Australia, Denmark, China, Korea, Republic of, Israel, Spain, France, Germany, Czechia, Austria, Japan, Sweden, United Kingdom, Greece, Italy, Finland, Argentina, Belgium, Brazil, Colombia, Hong Kong, India, Mexic... and more
Celgene

Recruiting

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)

Multiple Myeloma

Austria, Italy, China, Australia, Spain, United States, Korea, Republic of, Taiwan, Germany, Ireland, Argentina, Brazil, Mexico, Netherlands, Belgium, Czechia, France, Greece, Japan, Poland, Israel, United Kingdom, Norway, Denmark, Finland and more
Bristol-Myers Squibb
AbbVie

Completed

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (ELOQUENT - 2)

Lymphoma | Multiple Myeloma

United States, Belgium, France, Germany, Italy, Japan, United Kingdom, Australia, Poland, Puerto Rico, Canada, Denmark, Hungary, Israel, Spain, Czechia, Ireland, Austria, Switzerland, Greece, Turkey, Romania, United Arab Emirates
Novartis Pharmaceuticals

Recruiting

Pediatric Long-Term Follow-up and Rollover Study

Glioblastoma | Astrocytoma | Anaplastic Astrocytoma | Neurofibromatosis Type 1 | Anaplastic Ganglioglioma | Anaplastic Pleomorphic Xanthoastrocytoma | Ganglioglioma | Pleomorphic Xanthoastrocytoma | Diffuse Astrocytoma | Anaplastic Oligodendroglioma | Pilocytic Astrocytoma | Gangliocytoma | Central Neurocytoma | Oligodendroglioma... and other conditions

United States, Belgium, Spain, Denmark, Germany, Czechia, Italy, Australia, Russian Federation, Netherlands, Japan, Canada, Finland, Sweden, United Kingdom, Argentina, France, Brazil, Israel
Pfizer

Active, not recruiting

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer (CREST)

Non-muscle Invasive Bladder Cancer

China, United States, Spain, Belgium, Korea, Republic of, Australia, United Kingdom, Japan, France, Germany, Canada, Russian Federation, Poland, Italy
Takeda

Completed

A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

Multiple Myeloma

France, Spain, United States, Taiwan, Korea, Republic of, Israel, Australia, Czechia, Hungary, Canada, Japan, Portugal, Singapore, United Kingdom, Italy, Sweden, Poland, Germany, China, Denmark, Greece, Thailand, Serbia, Turkey, Colombia, Russian Federation and more
Amgen

Completed

Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients (ENDEAVOR)

Multiple Myeloma

Korea, Republic of, Spain, Taiwan, Canada, Australia, Israel, Italy, United States, Singapore, New Zealand, Japan, Thailand, Brazil, United Kingdom, Hungary, Czechia, Romania, Slovakia, France, Germany, Russian Federation, Bulgaria, Belgiu... and more

Clinical Trials on Transitional Cell, Carcinoma in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations